118 related articles for article (PubMed ID: 18314132)
1. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
Guyre CA; Gomes D; Smith KA; Kaplan JM; Perricone MA
J Immunol Methods; 2008 Apr; 333(1-2):51-60. PubMed ID: 18314132
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
3. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
4. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
[TBL] [Abstract][Full Text] [Related]
11. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
12. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
13. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
14. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
16. Campath-1H treatment of multiple sclerosis.
Jones JL; Coles AJ
Neurodegener Dis; 2008; 5(1):27-31. PubMed ID: 18075272
[TBL] [Abstract][Full Text] [Related]
17. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
Lowenstein H; Shah A; Chant A; Khan A
Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
[TBL] [Abstract][Full Text] [Related]
18. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
20. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
